<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" id="table1" position="float"><object-id pub-id-type="doi">10.7554/eLife.33478.004</object-id><label>Table 1.</label><caption><title>Baseline characteristics.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top">Variable</th><th valign="top">Placebo <break/>(n&#160;=&#160;41)</th><th valign="top">81 mg Aspirin (n&#160;=&#160;39)</th><th valign="top">1000 mg aspirin (n&#160;=&#160;40)</th></tr></thead><tbody><tr><td valign="top">Age (years) &#8211; median(IQR)</td><td valign="top">43 (33&#8211;49)</td><td valign="top">39 (34&#8211;48)</td><td valign="top">40 (31&#8211;53)</td></tr><tr><td valign="top">Male gender- no.(%)</td><td valign="top">27 (65.9)</td><td valign="top">28 (71.8)</td><td valign="top">24 (60.0)</td></tr><tr><td valign="top">Weight (kg)</td><td valign="top">50 (44&#8211;60)</td><td valign="top">50 (45&#8211;60)</td><td valign="top">50 (47&#8211;58)</td></tr><tr><td valign="top">Previous tuberculosis treatment- no.(%)</td><td valign="top">3 (7.3)</td><td valign="top">1 (2.6)</td><td valign="top">1 (2.5)</td></tr><tr><td valign="top">Illness duration (days) &#8211; median(IQR)</td><td valign="top">10 (9&#8211;14)</td><td valign="top">10 (8&#8211;15)</td><td valign="top">10 (8&#8211;14)</td></tr><tr><td valign="top">MRC Grade: &#8211; no.(%)* <break/>&#8195;- I <break/>&#8195;- II <break/>&#8195;- III</td><td valign="top"><break/>16 (39.0) <break/>20 (48.8) <break/>5 (12.2)</td><td valign="top"><break/>15 (38.5) <break/>19 (48.7) <break/>5 (12.8)</td><td valign="top"><break/>15 (37.5) <break/>20 (50.0) <break/>5 (12.5)</td></tr><tr><td valign="top">Glasgow Coma Score (/15) &#8211; median(IQR)</td><td valign="top">15 (14&#8211;15)</td><td valign="top">15 (14&#8211;15)</td><td valign="top">15 (14&#8211;15)</td></tr><tr><td valign="top">Cranial nerve palsy- no.(%)</td><td valign="top">12 (29.3)</td><td valign="top">9 (23.1)</td><td valign="top">12 (30.0)</td></tr><tr><td valign="top">Hemiplegia- no.(%)</td><td valign="top">3 (7.3)</td><td valign="top">0</td><td valign="top">1 (2.5)</td></tr><tr><td valign="top">Paraplegia- no.(%)</td><td valign="top">1 (2.4)</td><td valign="top">4 (10.3)</td><td valign="top">1 (2.5)</td></tr><tr><td valign="top">Chest radiograph: - no.(%) <break/>&#8195;- Normal <break/>&#8195;- Miliary tuberculosis <break/>&#8195;- Other lung tuberculosis</td><td valign="top"><break/>20 (48.8) <break/>10 (25.0) <break/>11 (26.8)</td><td valign="top"><break/>25 (64.1) <break/>3 (7.9) <break/>10 (25.6)</td><td valign="top"><break/>19 (47.5) <break/>11 (28.2) <break/>9 (22.5)</td></tr><tr><td valign="top">Plasma sodium (mmol/L) &#8211; median(IQR)</td><td valign="top">127 (124&#8211;131)</td><td valign="top">130 (125&#8211;134)</td><td valign="top">129 (125&#8211;132)</td></tr><tr><td valign="top">CSF: &#8211; median(IQR) <break/>Total leucocyte count (/mm<sup>3</sup>) <break/>% neutrophils <break/>% lymphocytes <break/>Total protein (g/dL) <break/>Lactate <break/>Glucose <break/>CSF:plasma glucose</td><td valign="top"><break/>311 (126&#8211;425) <break/>22 (7&#8211;49) <break/>78 (51&#8211;93) <break/>1.4 (1.1&#8211;2.0) <break/>5.0 (4.0&#8211;6.6) <break/>2.1 (1.3&#8211;2.8) <break/>0.3 (0.2&#8211;0.4)</td><td valign="top"><break/>328 (120&#8211;605) <break/>12 (6&#8211;29) <break/>88 (71&#8211;94) <break/>1.2 (0.9&#8211;1.9) <break/>5.0 (3.5&#8211;6.9) <break/>2.2 (1.7&#8211;2.9) <break/>0.3 (0.2&#8211;0.5)</td><td valign="top"><break/>180 (141&#8211;340) <break/>14 (6&#8211;32) <break/>84 (68&#8211;94) <break/>1.6 (1.1&#8211;2.1) <break/>4.9 (3.5&#8211;6.0) <break/>2.4 (1.7&#8211;2.8) <break/>0.4 (0.3&#8211;0.5)</td></tr><tr><td valign="top">Diagnostic category: - no.(%)<sup>&#8224;</sup> <break/>&#8195;- Definite <break/>&#8195;- Probable <break/>&#8195;- Possible <break/>&#8195;- Confirmed other diagnosis</td><td valign="top"><break/>34 (82.9) <break/>4 (9.8) <break/>2 (4.9) <break/>1 (2.4)</td><td valign="top"><break/>29 (74.4) <break/>5 (12.8) <break/>4 (10.3) <break/>1 (2.6)</td><td valign="top"><break/>29 (72.5) <break/>8 (20.0) <break/>3 (7.5) <break/>0</td></tr><tr><td valign="top">Brain imaging performed: - no.(%) <break/>&#8195;- Normal <break/>&#8195;- Meningeal enhancement <break/>&#8195;- Tuberculomas <break/>&#8195;- Hydrocephalus <break/>&#8195;- Infarcts</td><td valign="top">40 <break/>15 (37.5%) <break/>6 (15.0%) <break/>7 (17.5%) <break/>6 (15.0%) <break/>17 (42.5%)</td><td valign="top">35 <break/>13 (37.1%) <break/>5 (14.3%) <break/>4 (11.4%) <break/>4 (11.4%) <break/>8 (22.9%)</td><td valign="top">39 <break/>17 (43.6%) <break/>3 (7.7%) <break/>4 (10.3%) <break/>3 (7.7%) <break/>15 (38.5%)</td></tr><tr><td valign="top">DST available&#8211; no.<sup>&#8225;</sup> <break/>&#8195;- No isoniazid or rifampicin resistance &#8211; no.(%)<sup>&#167;</sup> <break/>&#8195;- Isoniazid resistant- no.(%) <break/>&#8195;- Rifampicin resistant- no.(%) <break/>&#8195;- MDR- no.(%)</td><td valign="top">19 <break/>12 (63.2) <break/><break/>6 (31.6) <break/>1 (5.2) <break/>0</td><td valign="top">9 <break/>7 (77.8) <break/><break/>1 (11.1) <break/>0 <break/>1 (11.1)</td><td valign="top">14 <break/>12 (86.7) <break/><break/>2 (14.3) <break/>0 <break/>0</td></tr><tr><td valign="top">Initial anti-tuberculosis drug treatment- no.(%)<sup>#</sup> <break/>&#8195;- RHZES <break/>&#8195;- RHZE <break/>&#8195;- RHZL</td><td valign="top"> <break/><break/>40 (97.6) <break/>1 (2.4) <break/>0</td><td valign="top"> <break/><break/>37 (94.9) <break/>1 (2.6) <break/>1 (2.6)</td><td valign="top"> <break/><break/>40 (100.0)</td></tr><tr><td valign="top">LTA4H genotype available &#8211; no <break/>&#8195;- CC <break/>&#8195;- CT <break/>&#8195;- TT</td><td valign="top">41 <break/>21 (51.2) <break/>16 (39.0) <break/>4 (9.8)</td><td valign="top">38 <break/>14 (36.8) <break/>18 (47.4) <break/>6 (15.8)</td><td valign="top">37 <break/>16 (43.2) <break/>20 (54.1) <break/>1 (2.7)</td></tr></tbody></table><table-wrap-foot><fn><p>IQR&#160;=&#160;inter quartile range</p><p>*MRC denotes modified British Medical Research Council criteria. Grade I indicates a Glasgow coma score of 15 with no neurologic signs, grade II a score of 11 to 14 (or 15 with focal neurologic signs), and grade III a score of 10 or less.</p></fn><fn><p><sup>&#8224;</sup>Diagnostic categories were assigned according to the consensus case definition (table S1) (<xref ref-type="bibr" rid="bib13">Marais et al., 2010</xref>). Confirmed other diagnosis was only made based on microbiological evidence.</p><p><sup>&#8225;</sup>DST&#160;=&#160;drug susceptibility test.</p></fn><fn><p><sup>&#167;</sup>MDR (multidrug-resistance) is defined as resistance to at least both isoniazid and rifampicin. In all categories, other resistance may be present.</p><p><sup>#</sup>Rifampicin (R), Isoniazid (H), Pyrazinamide, Ethambutol (E), Streptomycin (S).</p></fn></table-wrap-foot></table-wrap>